Tuta-Quintero Eduardo, Vega-Corredor María Camila, Perdomo-Rodríguez Laura Sofía, Pimentel Juan
Facultad de Medicina, Universidad de La Sabana, Chía, Colombia.
Departamento de Medicina Familiar y Salud Pública, Universidad de La Sabana, Chía, Colombia.
Rev Colomb Reumatol. 2022 Jun;29:S35-S47. doi: 10.1016/j.rcreu.2021.02.002. Epub 2021 Mar 27.
Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19.
To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection.
Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included.
A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies.
One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19.
秋水仙碱被广泛用于治疗痛风和地中海热等炎症性疾病。由于其免疫调节能力，它可能在新冠病毒疾病（COVID-19）的治疗中发挥重要作用。
探讨截至2020年12月28日已发表的关于秋水仙碱治疗确诊的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者的疗效和安全性的现有医学证据。
对包括PubMed和Scopus在内的文献进行范围综述。纳入英文和西班牙文的临床试验记录以及有实证数据的出版物（观察性和实验性研究）。
共找到33项临床试验和6篇出版物：前瞻性队列研究（n = 2）、回顾性队列研究（n = 2）、随机临床试验（n = 1）和病例对照研究（n = 1）。试验参与者总数为46,324人，73%（24/33）的研究正在招募参与者，51%（17/33）为3期研究。
一项临床试验报告称，SARS-CoV-2感染患者的预后炎症标志物有所下降，住院时间缩短。正在进行的临床试验将阐明秋水仙碱治疗COVID-19患者的疗效和安全性。
